Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 10, 2025Bone Marrow TransplantationOpen Access

Safety and efficacy of autologous humanized CD19 CAR-T cell therapy for relapsed/refractory B-cell non-Hodgkin lymphoma

View Full Paper
Ask AI
Bookmark
Share

Authors

YDYetian DongTYTingting YangMZMengyu Zhao

Discussion

Loading...

Member takes

Overview

Clinical trial reveals that CD19 CAR-T cells achieve an 80.8% response rate in relapsed/refractory B-cell non-Hodgkin lymphoma, highlighting safety and manageable toxicity.

Key Points

  • An 80.8% objective response was achieved among patients, with 69.2% attaining complete remission within 1 month post-infusion.
  • Only 1 patient experienced grade 3 cytokine release syndrome, indicating manageable toxicity of the therapy.
  • CAR-T expansion was observed in all patients, with a median peak of 220.63 cells/µL following infusion.
  • With a median follow-up of 20.3 months, 77.8% of complete remission patients remained in remission.

Cite This Study

Dong et al. (2025) studied this question.

synapsesocial.com/papers/68c242e0b210217d647a49b7https://doi.org/10.1038/s41409-025-02691-2
View Full Paper
Ask AI
Bookmark
Share